Lupin Limited’s revenue in Q3FY23 rose 13% to ₹ 1,97,66,301 lakhs. Consolidated Profit After Tax came at ₹ 8,34,871 lakhs in Q3FY23 showcasing a 3,851% rise on an YoY basis. In this quarter’s results, the reports suggested that the firm has continued to deliver consistent performance in all key operational and financial indicators in Q3Y23.
Lupin Limited Q3FY23; 47% Growth in Profits
Tags: Pharmaceutical
Related Post
- SMC Global Securities Ltd Q2FY25; 15% rise in Profits
SMC Global Securities Ltd (SMC) is a well-diversified financial service company in India & Abroad,…
-
Natco Pharma Ltd Q2FY25; 83% rise in Profits
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged…
-
Muthoot Finance Ltd Q2FY25; 26% rise in Profits
Muthoot Finance is NBFC engaged in the business of providing gold loans. The company predominately…